Location: Vienna, Austria
Date: May 26 to May 29
European Society of Cardiology on Acute Hearth Failure
SGLT2 inhibition and heart failure: time to think differently? - Heart failure: The whole picture in 5 minutes
Lessons learnt from recent clinical trial outcomes - Why was CANTOS positive - What can we learn for basic science?
Interpretation of biomarkers in chronic heart failure – Easier said than done - Established biomarkers - Who is hot and who is not?
Acute heart failure: from drugs to devices and back - Mihai Gheorghiade lecture - The future in heart failure therapeutics: restore and regenerate
Atrial fibrillation and HFpEF - Just twins? - Pharmacological therapies in atrial fibrillation and HFpEF
Rene Lerch Session - Gaps in evidence - HFmrEF - Playground for subgroup analysts or a real clinical problem?
Heart failure as a major local and global challenge in the 21st century - Epidemiology in Hungary
GRAND DEBATE I - Drugs or interventions - The beat goes on - Coronary revascularisation provides no meaningful clinical benefit over optimal medical therapy in patients with stable ischaemic heart failure - CONTRA